nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—HTR1A—stomach cancer	0.528	1	CbGaD
Ergotamine—ABCB1—Mitomycin—stomach cancer	0.0672	0.425	CbGbCtD
Ergotamine—CYP1A2—Fluorouracil—stomach cancer	0.0189	0.12	CbGbCtD
Ergotamine—ABCB1—Irinotecan—stomach cancer	0.0172	0.109	CbGbCtD
Ergotamine—Ischaemia—Floxuridine—stomach cancer	0.0132	0.183	CcSEcCtD
Ergotamine—ABCB1—Docetaxel—stomach cancer	0.0126	0.0799	CbGbCtD
Ergotamine—CYP3A4—Irinotecan—stomach cancer	0.0103	0.0653	CbGbCtD
Ergotamine—ABCB1—Doxorubicin—stomach cancer	0.00942	0.0596	CbGbCtD
Ergotamine—ABCB1—Methotrexate—stomach cancer	0.00912	0.0577	CbGbCtD
Ergotamine—CYP3A4—Docetaxel—stomach cancer	0.00757	0.0479	CbGbCtD
Ergotamine—HTR2A—myenteric nerve plexus—stomach cancer	0.00597	0.131	CbGeAlD
Ergotamine—CYP3A4—Doxorubicin—stomach cancer	0.00564	0.0357	CbGbCtD
Ergotamine—Ischaemia—Irinotecan—stomach cancer	0.0045	0.0625	CcSEcCtD
Ergotamine—Localised oedema—Capecitabine—stomach cancer	0.00435	0.0604	CcSEcCtD
Ergotamine—Paresthesia of limbs—Methotrexate—stomach cancer	0.00427	0.0593	CcSEcCtD
Ergotamine—HTR2A—vagus nerve—stomach cancer	0.00398	0.0876	CbGeAlD
Ergotamine—HTR2A—vein—stomach cancer	0.00385	0.0847	CbGeAlD
Ergotamine—Emotional distress—Fluorouracil—stomach cancer	0.0037	0.0514	CcSEcCtD
Ergotamine—HTR1B—blood vessel—stomach cancer	0.00254	0.0559	CbGeAlD
Ergotamine—HTR1D—blood vessel—stomach cancer	0.00246	0.0541	CbGeAlD
Ergotamine—Peripheral coldness—Capecitabine—stomach cancer	0.00231	0.0321	CcSEcCtD
Ergotamine—Numbness—Fluorouracil—stomach cancer	0.0019	0.0264	CcSEcCtD
Ergotamine—Sensory loss—Fluorouracil—stomach cancer	0.00182	0.0252	CcSEcCtD
Ergotamine—ADRA1D—epithelium—stomach cancer	0.0016	0.0352	CbGeAlD
Ergotamine—Dihydroergotamine—HTR1A—stomach cancer	0.00158	0.259	CrCbGaD
Ergotamine—Hypertension—Mitomycin—stomach cancer	0.00143	0.0198	CcSEcCtD
Ergotamine—Asthenia—Floxuridine—stomach cancer	0.00123	0.0171	CcSEcCtD
Ergotamine—HTR2A—blood vessel—stomach cancer	0.00122	0.0269	CbGeAlD
Ergotamine—Cyanosis—Methotrexate—stomach cancer	0.00116	0.0161	CcSEcCtD
Ergotamine—Pain—Mitomycin—stomach cancer	0.00115	0.016	CcSEcCtD
Ergotamine—Vomiting—Floxuridine—stomach cancer	0.00109	0.0152	CcSEcCtD
Ergotamine—HTR1A—hematopoietic system—stomach cancer	0.00109	0.024	CbGeAlD
Ergotamine—HTR2B—smooth muscle tissue—stomach cancer	0.00107	0.0236	CbGeAlD
Ergotamine—Methysergide—HTR1A—stomach cancer	0.00105	0.173	CrCbGaD
Ergotamine—Nausea—Floxuridine—stomach cancer	0.00102	0.0142	CcSEcCtD
Ergotamine—ADRA1D—endocrine gland—stomach cancer	0.00101	0.0221	CbGeAlD
Ergotamine—ADRA1A—hematopoietic system—stomach cancer	0.00101	0.0221	CbGeAlD
Ergotamine—Asthenia—Mitomycin—stomach cancer	0.000968	0.0134	CcSEcCtD
Ergotamine—Lisuride—ADRB1—stomach cancer	0.000947	0.155	CrCbGaD
Ergotamine—ADRA1A—epithelium—stomach cancer	0.000919	0.0202	CbGeAlD
Ergotamine—Bromocriptine—ADRB1—stomach cancer	0.000877	0.144	CrCbGaD
Ergotamine—Vomiting—Mitomycin—stomach cancer	0.000858	0.0119	CcSEcCtD
Ergotamine—Lisuride—HTR1A—stomach cancer	0.000847	0.139	CrCbGaD
Ergotamine—HTR2B—digestive system—stomach cancer	0.000846	0.0186	CbGeAlD
Ergotamine—Bradycardia—Irinotecan—stomach cancer	0.00084	0.0117	CcSEcCtD
Ergotamine—CYP1A2—hematopoietic system—stomach cancer	0.000831	0.0183	CbGeAlD
Ergotamine—Nausea—Mitomycin—stomach cancer	0.000801	0.0111	CcSEcCtD
Ergotamine—ABCB1—blood vessel—stomach cancer	0.0008	0.0176	CbGeAlD
Ergotamine—Hypoaesthesia—Fluorouracil—stomach cancer	0.000786	0.0109	CcSEcCtD
Ergotamine—Bromocriptine—HTR1A—stomach cancer	0.000785	0.129	CrCbGaD
Ergotamine—HTR1B—endocrine gland—stomach cancer	0.000776	0.0171	CbGeAlD
Ergotamine—ADRA2A—hematopoietic system—stomach cancer	0.000764	0.0168	CbGeAlD
Ergotamine—ADRA1A—lymphoid tissue—stomach cancer	0.000708	0.0156	CbGeAlD
Ergotamine—HTR2A—hematopoietic system—stomach cancer	0.00065	0.0143	CbGeAlD
Ergotamine—Vertigo—Irinotecan—stomach cancer	0.000645	0.00896	CcSEcCtD
Ergotamine—HTR1A—endocrine gland—stomach cancer	0.000627	0.0138	CbGeAlD
Ergotamine—ADRA2A—pancreas—stomach cancer	0.000622	0.0137	CbGeAlD
Ergotamine—SLC6A2—endocrine gland—stomach cancer	0.000621	0.0137	CbGeAlD
Ergotamine—Hypertension—Irinotecan—stomach cancer	0.00062	0.00861	CcSEcCtD
Ergotamine—CYP3A4—hematopoietic system—stomach cancer	0.000602	0.0132	CbGeAlD
Ergotamine—HTR2A—epithelium—stomach cancer	0.000594	0.0131	CbGeAlD
Ergotamine—Myalgia—Fluorouracil—stomach cancer	0.000585	0.00813	CcSEcCtD
Ergotamine—CYP1A2—digestive system—stomach cancer	0.000578	0.0127	CbGeAlD
Ergotamine—ADRA1A—endocrine gland—stomach cancer	0.000578	0.0127	CbGeAlD
Ergotamine—HTR2A—smooth muscle tissue—stomach cancer	0.000572	0.0126	CbGeAlD
Ergotamine—Hypoaesthesia—Docetaxel—stomach cancer	0.000567	0.00788	CcSEcCtD
Ergotamine—DRD2—endocrine gland—stomach cancer	0.000566	0.0125	CbGeAlD
Ergotamine—Bradycardia—Capecitabine—stomach cancer	0.000562	0.0078	CcSEcCtD
Ergotamine—Hypoaesthesia—Capecitabine—stomach cancer	0.000549	0.00763	CcSEcCtD
Ergotamine—Tachycardia—Fluorouracil—stomach cancer	0.000548	0.00761	CcSEcCtD
Ergotamine—Paraesthesia—Irinotecan—stomach cancer	0.000526	0.00731	CcSEcCtD
Ergotamine—ADRA1A—liver—stomach cancer	0.000521	0.0115	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Fluorouracil—stomach cancer	0.000511	0.0071	CcSEcCtD
Ergotamine—Paraesthesia—Fluorouracil—stomach cancer	0.000504	0.007	CcSEcCtD
Ergotamine—Pain—Irinotecan—stomach cancer	0.000501	0.00696	CcSEcCtD
Ergotamine—HTR2B—lymph node—stomach cancer	0.000483	0.0106	CbGeAlD
Ergotamine—Pain—Fluorouracil—stomach cancer	0.00048	0.00667	CcSEcCtD
Ergotamine—CYP1A2—endocrine gland—stomach cancer	0.000478	0.0105	CbGeAlD
Ergotamine—HTR2A—digestive system—stomach cancer	0.000452	0.00995	CbGeAlD
Ergotamine—ADRA2A—endocrine gland—stomach cancer	0.000439	0.00967	CbGeAlD
Ergotamine—Vertigo—Capecitabine—stomach cancer	0.000432	0.006	CcSEcCtD
Ergotamine—CYP1A2—liver—stomach cancer	0.000431	0.00948	CbGeAlD
Ergotamine—SLC6A2—lymph node—stomach cancer	0.000429	0.00946	CbGeAlD
Ergotamine—Hypertension—Docetaxel—stomach cancer	0.000428	0.00595	CcSEcCtD
Ergotamine—ABCB1—hematopoietic system—stomach cancer	0.000426	0.00938	CbGeAlD
Ergotamine—Myalgia—Docetaxel—stomach cancer	0.000423	0.00587	CcSEcCtD
Ergotamine—Asthenia—Irinotecan—stomach cancer	0.00042	0.00584	CcSEcCtD
Ergotamine—CYP3A4—digestive system—stomach cancer	0.000418	0.00921	CbGeAlD
Ergotamine—Hypertension—Capecitabine—stomach cancer	0.000415	0.00576	CcSEcCtD
Ergotamine—Myalgia—Capecitabine—stomach cancer	0.000409	0.00568	CcSEcCtD
Ergotamine—Pruritus—Fluorouracil—stomach cancer	0.000397	0.00551	CcSEcCtD
Ergotamine—Tachycardia—Docetaxel—stomach cancer	0.000395	0.00549	CcSEcCtD
Ergotamine—Bradycardia—Epirubicin—stomach cancer	0.000391	0.00544	CcSEcCtD
Ergotamine—ABCB1—epithelium—stomach cancer	0.000389	0.00857	CbGeAlD
Ergotamine—Tachycardia—Capecitabine—stomach cancer	0.000383	0.00532	CcSEcCtD
Ergotamine—Hypoaesthesia—Epirubicin—stomach cancer	0.000383	0.00531	CcSEcCtD
Ergotamine—HTR2A—endocrine gland—stomach cancer	0.000373	0.00822	CbGeAlD
Ergotamine—Vomiting—Irinotecan—stomach cancer	0.000373	0.00517	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000369	0.00513	CcSEcCtD
Ergotamine—Paraesthesia—Docetaxel—stomach cancer	0.000364	0.00505	CcSEcCtD
Ergotamine—Bradycardia—Doxorubicin—stomach cancer	0.000362	0.00503	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000357	0.00496	CcSEcCtD
Ergotamine—Vomiting—Fluorouracil—stomach cancer	0.000357	0.00496	CcSEcCtD
Ergotamine—Hypoaesthesia—Doxorubicin—stomach cancer	0.000354	0.00492	CcSEcCtD
Ergotamine—Paraesthesia—Capecitabine—stomach cancer	0.000352	0.00489	CcSEcCtD
Ergotamine—Nausea—Irinotecan—stomach cancer	0.000348	0.00483	CcSEcCtD
Ergotamine—ABCB1—pancreas—stomach cancer	0.000347	0.00763	CbGeAlD
Ergotamine—Pain—Docetaxel—stomach cancer	0.000346	0.00481	CcSEcCtD
Ergotamine—CYP3A4—endocrine gland—stomach cancer	0.000346	0.00761	CbGeAlD
Ergotamine—HTR2A—liver—stomach cancer	0.000337	0.00741	CbGeAlD
Ergotamine—Pain—Capecitabine—stomach cancer	0.000335	0.00466	CcSEcCtD
Ergotamine—Nausea—Fluorouracil—stomach cancer	0.000333	0.00463	CcSEcCtD
Ergotamine—Vertigo—Methotrexate—stomach cancer	0.000321	0.00446	CcSEcCtD
Ergotamine—CYP3A4—liver—stomach cancer	0.000312	0.00686	CbGeAlD
Ergotamine—Myalgia—Methotrexate—stomach cancer	0.000305	0.00423	CcSEcCtD
Ergotamine—ADRA2A—lymph node—stomach cancer	0.000304	0.00668	CbGeAlD
Ergotamine—Vertigo—Epirubicin—stomach cancer	0.000301	0.00418	CcSEcCtD
Ergotamine—ABCB1—lymphoid tissue—stomach cancer	0.0003	0.0066	CbGeAlD
Ergotamine—ABCB1—digestive system—stomach cancer	0.000296	0.00652	CbGeAlD
Ergotamine—Asthenia—Docetaxel—stomach cancer	0.000291	0.00404	CcSEcCtD
Ergotamine—Hypertension—Epirubicin—stomach cancer	0.000289	0.00401	CcSEcCtD
Ergotamine—Pruritus—Docetaxel—stomach cancer	0.000287	0.00398	CcSEcCtD
Ergotamine—Myalgia—Epirubicin—stomach cancer	0.000285	0.00396	CcSEcCtD
Ergotamine—Asthenia—Capecitabine—stomach cancer	0.000281	0.00391	CcSEcCtD
Ergotamine—Vertigo—Doxorubicin—stomach cancer	0.000278	0.00386	CcSEcCtD
Ergotamine—Pruritus—Capecitabine—stomach cancer	0.000277	0.00385	CcSEcCtD
Ergotamine—ABCB1—bone marrow—stomach cancer	0.000273	0.00601	CbGeAlD
Ergotamine—Hypertension—Doxorubicin—stomach cancer	0.000267	0.00371	CcSEcCtD
Ergotamine—Tachycardia—Epirubicin—stomach cancer	0.000267	0.0037	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000266	0.00369	CcSEcCtD
Ergotamine—Myalgia—Doxorubicin—stomach cancer	0.000264	0.00366	CcSEcCtD
Ergotamine—Paraesthesia—Methotrexate—stomach cancer	0.000262	0.00364	CcSEcCtD
Ergotamine—Vomiting—Docetaxel—stomach cancer	0.000258	0.00358	CcSEcCtD
Ergotamine—Pain—Methotrexate—stomach cancer	0.00025	0.00347	CcSEcCtD
Ergotamine—Vomiting—Capecitabine—stomach cancer	0.000249	0.00346	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000249	0.00346	CcSEcCtD
Ergotamine—Tachycardia—Doxorubicin—stomach cancer	0.000247	0.00343	CcSEcCtD
Ergotamine—Paraesthesia—Epirubicin—stomach cancer	0.000245	0.00341	CcSEcCtD
Ergotamine—ABCB1—endocrine gland—stomach cancer	0.000245	0.00539	CbGeAlD
Ergotamine—Nausea—Docetaxel—stomach cancer	0.000241	0.00334	CcSEcCtD
Ergotamine—Pain—Epirubicin—stomach cancer	0.000234	0.00324	CcSEcCtD
Ergotamine—Nausea—Capecitabine—stomach cancer	0.000233	0.00324	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.00023	0.0032	CcSEcCtD
Ergotamine—Paraesthesia—Doxorubicin—stomach cancer	0.000227	0.00315	CcSEcCtD
Ergotamine—ABCB1—liver—stomach cancer	0.000221	0.00486	CbGeAlD
Ergotamine—Pain—Doxorubicin—stomach cancer	0.000216	0.003	CcSEcCtD
Ergotamine—Asthenia—Methotrexate—stomach cancer	0.000209	0.00291	CcSEcCtD
Ergotamine—Pruritus—Methotrexate—stomach cancer	0.000207	0.00287	CcSEcCtD
Ergotamine—Asthenia—Epirubicin—stomach cancer	0.000196	0.00272	CcSEcCtD
Ergotamine—Pruritus—Epirubicin—stomach cancer	0.000193	0.00268	CcSEcCtD
Ergotamine—Vomiting—Methotrexate—stomach cancer	0.000186	0.00258	CcSEcCtD
Ergotamine—Asthenia—Doxorubicin—stomach cancer	0.000181	0.00252	CcSEcCtD
Ergotamine—Pruritus—Doxorubicin—stomach cancer	0.000179	0.00248	CcSEcCtD
Ergotamine—Vomiting—Epirubicin—stomach cancer	0.000174	0.00241	CcSEcCtD
Ergotamine—Nausea—Methotrexate—stomach cancer	0.000173	0.00241	CcSEcCtD
Ergotamine—ABCB1—lymph node—stomach cancer	0.000169	0.00372	CbGeAlD
Ergotamine—Nausea—Epirubicin—stomach cancer	0.000162	0.00225	CcSEcCtD
Ergotamine—Vomiting—Doxorubicin—stomach cancer	0.000161	0.00223	CcSEcCtD
Ergotamine—Nausea—Doxorubicin—stomach cancer	0.00015	0.00209	CcSEcCtD
Ergotamine—HTR2C—Signaling Pathways—CXCL8—stomach cancer	6.25e-06	3.29e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—HRAS—stomach cancer	6.25e-06	3.29e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—STAT3—stomach cancer	6.23e-06	3.28e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6R—stomach cancer	6.23e-06	3.28e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NOS3—stomach cancer	6.22e-06	3.27e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—KRAS—stomach cancer	6.22e-06	3.27e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—HRAS—stomach cancer	6.21e-06	3.27e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL6—stomach cancer	6.19e-06	3.26e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—RHOA—stomach cancer	6.19e-06	3.26e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MYC—stomach cancer	6.17e-06	3.24e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MAPK1—stomach cancer	6.16e-06	3.24e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EGFR—stomach cancer	6.16e-06	3.24e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDKN1B—stomach cancer	6.14e-06	3.23e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NOS3—stomach cancer	6.12e-06	3.22e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—MAPK1—stomach cancer	6.11e-06	3.22e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—EGFR—stomach cancer	6.11e-06	3.22e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1B—stomach cancer	6.11e-06	3.21e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—stomach cancer	6.09e-06	3.21e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CAV1—stomach cancer	6.09e-06	3.21e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—APOA1—stomach cancer	6.08e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCND1—stomach cancer	6.07e-06	3.19e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—RHOA—stomach cancer	6.06e-06	3.19e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—JUN—stomach cancer	6.05e-06	3.19e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TYMS—stomach cancer	6.03e-06	3.18e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MAPK1—stomach cancer	6.03e-06	3.17e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EGFR—stomach cancer	6.03e-06	3.17e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CD44—stomach cancer	6.01e-06	3.16e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NOS3—stomach cancer	5.99e-06	3.15e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCL8—stomach cancer	5.99e-06	3.15e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL6—stomach cancer	5.98e-06	3.15e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTM1—stomach cancer	5.97e-06	3.14e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK3—stomach cancer	5.96e-06	3.13e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HRAS—stomach cancer	5.95e-06	3.13e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL6—stomach cancer	5.95e-06	3.13e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—PIK3CA—stomach cancer	5.93e-06	3.12e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MMP9—stomach cancer	5.89e-06	3.1e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CDKN1A—stomach cancer	5.87e-06	3.09e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—VEGFA—stomach cancer	5.86e-06	3.08e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCND1—stomach cancer	5.86e-06	3.08e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1B—stomach cancer	5.85e-06	3.08e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—JUN—stomach cancer	5.84e-06	3.08e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—stomach cancer	5.84e-06	3.07e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SERPINE1—stomach cancer	5.83e-06	3.07e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—PIK3CA—stomach cancer	5.83e-06	3.07e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCND1—stomach cancer	5.83e-06	3.07e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—ERBB2—stomach cancer	5.82e-06	3.06e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—KRAS—stomach cancer	5.82e-06	3.06e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—JUN—stomach cancer	5.81e-06	3.06e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—STAT3—stomach cancer	5.8e-06	3.05e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MYC—stomach cancer	5.79e-06	3.05e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—KRAS—stomach cancer	5.77e-06	3.04e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK8—stomach cancer	5.73e-06	3.01e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—ERBB2—stomach cancer	5.73e-06	3.01e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—PIK3CA—stomach cancer	5.71e-06	3e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—KRAS—stomach cancer	5.7e-06	3e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—stomach cancer	5.69e-06	3e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MMP9—stomach cancer	5.69e-06	2.99e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK1—stomach cancer	5.67e-06	2.98e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—stomach cancer	5.67e-06	2.98e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDKN1A—stomach cancer	5.67e-06	2.98e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MMP9—stomach cancer	5.66e-06	2.98e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1A—stomach cancer	5.64e-06	2.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RHOA—stomach cancer	5.63e-06	2.96e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ERCC2—stomach cancer	5.61e-06	2.95e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ERBB2—stomach cancer	5.61e-06	2.95e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—stomach cancer	5.58e-06	2.93e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOS3—stomach cancer	5.57e-06	2.93e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—JUN—stomach cancer	5.57e-06	2.93e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK3—stomach cancer	5.54e-06	2.92e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK8—stomach cancer	5.53e-06	2.91e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—stomach cancer	5.52e-06	2.9e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK8—stomach cancer	5.5e-06	2.89e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—stomach cancer	5.48e-06	2.89e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—stomach cancer	5.43e-06	2.86e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—stomach cancer	5.41e-06	2.85e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—stomach cancer	5.4e-06	2.84e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—stomach cancer	5.4e-06	2.84e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—stomach cancer	5.39e-06	2.84e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1B—stomach cancer	5.39e-06	2.84e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARG—stomach cancer	5.36e-06	2.82e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—stomach cancer	5.35e-06	2.82e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—stomach cancer	5.35e-06	2.81e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—stomach cancer	5.32e-06	2.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—stomach cancer	5.31e-06	2.79e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1B—stomach cancer	5.3e-06	2.79e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—stomach cancer	5.29e-06	2.78e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—stomach cancer	5.28e-06	2.78e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK1—stomach cancer	5.27e-06	2.77e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—stomach cancer	5.27e-06	2.77e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—stomach cancer	5.27e-06	2.77e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK8—stomach cancer	5.27e-06	2.77e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—stomach cancer	5.25e-06	2.76e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—stomach cancer	5.24e-06	2.76e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—stomach cancer	5.23e-06	2.75e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—stomach cancer	5.21e-06	2.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1B—stomach cancer	5.19e-06	2.73e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—stomach cancer	5.17e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—stomach cancer	5.16e-06	2.72e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—stomach cancer	5.14e-06	2.71e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—JUN—stomach cancer	5.13e-06	2.7e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPP2R1A—stomach cancer	5.11e-06	2.69e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—stomach cancer	5.11e-06	2.69e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—stomach cancer	5.08e-06	2.67e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—stomach cancer	5.06e-06	2.66e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—stomach cancer	5.06e-06	2.66e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—stomach cancer	5.06e-06	2.66e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—stomach cancer	5.06e-06	2.66e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—JUN—stomach cancer	5.05e-06	2.66e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—stomach cancer	5.03e-06	2.65e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTP1—stomach cancer	5.01e-06	2.64e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—stomach cancer	5e-06	2.63e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—stomach cancer	4.99e-06	2.63e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—stomach cancer	4.98e-06	2.62e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—stomach cancer	4.97e-06	2.62e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—stomach cancer	4.95e-06	2.61e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—stomach cancer	4.95e-06	2.6e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—JUN—stomach cancer	4.94e-06	2.6e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMOX1—stomach cancer	4.94e-06	2.6e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—stomach cancer	4.94e-06	2.6e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—stomach cancer	4.92e-06	2.59e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—stomach cancer	4.91e-06	2.58e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—stomach cancer	4.91e-06	2.58e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—stomach cancer	4.89e-06	2.58e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—stomach cancer	4.87e-06	2.56e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CAV1—stomach cancer	4.86e-06	2.56e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—stomach cancer	4.86e-06	2.56e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK8—stomach cancer	4.85e-06	2.55e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOA1—stomach cancer	4.85e-06	2.55e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—stomach cancer	4.84e-06	2.55e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—stomach cancer	4.83e-06	2.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1B—stomach cancer	4.82e-06	2.54e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—stomach cancer	4.82e-06	2.53e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—stomach cancer	4.81e-06	2.53e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—stomach cancer	4.81e-06	2.53e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—stomach cancer	4.8e-06	2.53e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—stomach cancer	4.79e-06	2.52e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK8—stomach cancer	4.78e-06	2.51e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK1—stomach cancer	4.76e-06	2.51e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—stomach cancer	4.76e-06	2.5e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—stomach cancer	4.76e-06	2.5e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—stomach cancer	4.73e-06	2.49e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—stomach cancer	4.7e-06	2.47e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—stomach cancer	4.7e-06	2.47e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK8—stomach cancer	4.68e-06	2.46e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—stomach cancer	4.67e-06	2.46e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TYMS—stomach cancer	4.66e-06	2.45e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.65e-06	2.44e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—stomach cancer	4.64e-06	2.44e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NOS3—stomach cancer	4.61e-06	2.42e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—stomach cancer	4.6e-06	2.42e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—stomach cancer	4.6e-06	2.42e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—stomach cancer	4.6e-06	2.42e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK1—stomach cancer	4.6e-06	2.42e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—stomach cancer	4.59e-06	2.42e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JUN—stomach cancer	4.59e-06	2.42e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—stomach cancer	4.58e-06	2.41e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK1—stomach cancer	4.57e-06	2.41e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—stomach cancer	4.57e-06	2.41e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—stomach cancer	4.55e-06	2.39e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—stomach cancer	4.5e-06	2.37e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—stomach cancer	4.48e-06	2.36e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—stomach cancer	4.47e-06	2.35e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—stomach cancer	4.47e-06	2.35e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—stomach cancer	4.45e-06	2.34e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—stomach cancer	4.44e-06	2.34e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—stomach cancer	4.43e-06	2.33e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—stomach cancer	4.41e-06	2.32e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK1—stomach cancer	4.38e-06	2.3e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—stomach cancer	4.38e-06	2.3e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—stomach cancer	4.37e-06	2.3e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—stomach cancer	4.35e-06	2.29e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK8—stomach cancer	4.35e-06	2.29e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—stomach cancer	4.34e-06	2.28e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—stomach cancer	4.33e-06	2.28e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—stomach cancer	4.32e-06	2.27e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—stomach cancer	4.32e-06	2.27e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—stomach cancer	4.28e-06	2.25e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARG—stomach cancer	4.28e-06	2.25e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—stomach cancer	4.24e-06	2.23e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—stomach cancer	4.23e-06	2.23e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—stomach cancer	4.21e-06	2.22e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—stomach cancer	4.17e-06	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—stomach cancer	4.13e-06	2.18e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—stomach cancer	4.13e-06	2.17e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—stomach cancer	4.12e-06	2.17e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—stomach cancer	4.09e-06	2.15e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—stomach cancer	4.07e-06	2.14e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—stomach cancer	4.06e-06	2.14e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—stomach cancer	4.05e-06	2.13e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK1—stomach cancer	4.03e-06	2.12e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—stomach cancer	4.03e-06	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—stomach cancer	4.01e-06	2.11e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—stomach cancer	4e-06	2.1e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—stomach cancer	3.99e-06	2.1e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—stomach cancer	3.97e-06	2.09e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—stomach cancer	3.97e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK1—stomach cancer	3.97e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—stomach cancer	3.97e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—stomach cancer	3.97e-06	2.09e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK1—stomach cancer	3.89e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—stomach cancer	3.89e-06	2.05e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—stomach cancer	3.86e-06	2.03e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—stomach cancer	3.84e-06	2.02e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—stomach cancer	3.84e-06	2.02e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—stomach cancer	3.82e-06	2.01e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—stomach cancer	3.81e-06	2.01e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—stomach cancer	3.8e-06	2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—stomach cancer	3.8e-06	2e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAV1—stomach cancer	3.75e-06	1.97e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—stomach cancer	3.75e-06	1.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—stomach cancer	3.75e-06	1.97e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOA1—stomach cancer	3.74e-06	1.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—stomach cancer	3.69e-06	1.94e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—stomach cancer	3.69e-06	1.94e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NOS3—stomach cancer	3.68e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—stomach cancer	3.67e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—stomach cancer	3.67e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—stomach cancer	3.67e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—stomach cancer	3.66e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK1—stomach cancer	3.61e-06	1.9e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—stomach cancer	3.61e-06	1.9e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—stomach cancer	3.53e-06	1.86e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—stomach cancer	3.51e-06	1.85e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—stomach cancer	3.51e-06	1.85e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—stomach cancer	3.5e-06	1.84e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—stomach cancer	3.44e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—stomach cancer	3.41e-06	1.8e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—stomach cancer	3.39e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—stomach cancer	3.37e-06	1.78e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—stomach cancer	3.36e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—stomach cancer	3.36e-06	1.77e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—stomach cancer	3.33e-06	1.75e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARG—stomach cancer	3.3e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—stomach cancer	3.26e-06	1.72e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—stomach cancer	3.24e-06	1.7e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—stomach cancer	3.19e-06	1.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—stomach cancer	3.13e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—stomach cancer	3.12e-06	1.64e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—stomach cancer	3.1e-06	1.63e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—stomach cancer	3.05e-06	1.61e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—stomach cancer	3.03e-06	1.6e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—stomach cancer	2.99e-06	1.57e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—stomach cancer	2.97e-06	1.56e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—stomach cancer	2.9e-06	1.53e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NOS3—stomach cancer	2.84e-06	1.49e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—stomach cancer	2.78e-06	1.46e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—stomach cancer	2.6e-06	1.37e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—stomach cancer	2.59e-06	1.36e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—stomach cancer	2.07e-06	1.09e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.6e-06	8.4e-06	CbGpPWpGaD
